Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer Guideline Update

About this episode

The episode discusses updated guidelines on immunotherapy and targeted therapy for advanced gastroesophageal cancer.

Dr. Lakshmi Rajdev and Dr. Manish Shah join the podcast to discuss the updated guideline on immunotherapy and targeted therapy in unresectable locally advanced, advanced, or metastatic gastroesophageal cancer. They share first-line and subsequent-line recommendations for both gastroesophageal adenocarcinoma and esophageal squamous cell carcinoma based on actionable biomarkers including PD-L1 expression, MMR and/or MSI, CLDN18.2 expression, and HER2 status. They note the importance of the algorithms and tables in the guidelines that provide visual illustrations and quick reference guides of the evidence-based recommendations. They also comment on ongoing and recently presented trials that may impact future guidelines in this space. Read the full guideline, " Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update " at www.asco.org/gastrointestinal-cancer-guidelines" TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/gastrointestinal-cancer-guidelines . Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology…

People in this episode

Guests: Dr. Lakshmi Rajdev, Dr. Manish Shah

Topics covered

• immunotherapy
• targeted therapy
• gastroesophageal cancer
• clinical guidelines
• biomarkers
• cancer treatment

Keywords

• gastroesophageal adenocarcinoma
• esophageal squamous cell carcinoma
• PD-L1 expression
• MMR
• MSI
• CLDN18.2 expression
• HER2 status
• clinical trials
• evidence-based recommendations

Mentioned in this episode

Organizations: American Society of Clinical Oncology, Journal of Clinical Oncology, asco.org

Books & works: Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update

More episodes of ASCO Guidelines

• Systemic Treatment of Thyroid Cancer Guideline · April 1, 2026 · 23 min
• Patient-Clinician Communication Guideline Update · March 10, 2026 · 31 min
• White Blood Cell Growth Factors Guideline Update · February 25, 2026 · 23 min
• Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2026.3.0 Part 2 · February 3, 2026 · 20 min
• Therapy for Stage IV NSCLC Without Driver Alterations: ASCO Living Guideline Update 2026.3.0 Part 1 · February 3, 2026 · 18 min
• Systemic Therapy in Patients With mCRPC: ASCO Living Guideline 2026.1 · January 20, 2026 · 14 min